Fig. 3
From: Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Therapeutic effects of EGCG/AA NPs in the APP/PS1 mouse model of AD. a GFAP and ThS immunostaining indicate the status of neuroinflammation and Aβ plaque deposition, respectively. Bar diagrams demonstrate the reduction in Aβ plaque deposition at the b hippocampus and c cortex area. d Percentage cumulative drug release showed sustained drug release of EGCG/AA NPs over free EGCG. e Schematic diagram of therapeutic effects of EGCG/AA NPs in an AD mouse model. Data are expressed as the mean ± SEM *P < 0.01, **P < 0.01, ***P < 0.001, ****P < 0.0001. Reproduced from ref. 114
